- Research Article
- Open access
- Published:
Assessment of Arterial Stiffness by Brachial Oscillometry in Community Pharmacies for Managing Hypertension (COPHARTEN)
Artery Research volume 25, pages 121–130 (2019)
Abstract
Background and Objective
Arterial Stiffness (AS) measured as pulse wave velocity has emerged in recent years as a hypertension mediated organ damage with independent prognostic value for Cardiovascular (CV) diseases that has also been discussed as a potential cause of Hypertension (HTN). The aim of this study is to (1) evaluate how measurement of AS modifies CV risk calculation by SCORE, (2) to measure the predictive value of AS for incident hypertension in normotensive patients, and (3) to analyze the association between control of HTN and presence of AS in sustained HTN.
Patients and Methods
A longitudinal, prospective, observational trial under conditions of daily pharmaceutical and clinical practice will be conducted in approximately 60 community pharmacies of the Iberian Peninsula in normotensive and/or hypertensive patients entering a pharmacy spontaneously. In the first cross-sectional step, AS will be estimated with a semiautomatic, validated device (Mobil-O-Graph®, IEM), followed by a 10-item questionnaire. The patients will be referred to Primary Care for stratifying risk by SCORE tables and standard evaluation. In the second longitudinal step, patients will be asked to repeat the visit after 12 months.
Discussion
This study aims to improve CV risk stratification and to investigate the potential of AS in predicting incident HTN in normotensive subjects. Besides, it will analyze the role of arterial stiffness as an associated factor to prevent control in sustained HTN in a setting of cooperation between community pharmacies and physicians in daily clinical practice.
References
Encuesta Nacional de Salud, ENSE. INEbase – https://www.ines.es; 2014.
Banegas JRB, Rodríguez Artalejo F. [The problem of arterial hypertension in Spain]. Rev Clin Esp 2002;202:12–15 [Article in Spanish].
Desgraz B, Collet TH, Rodondi N, Cornuz J, Clair C. Comparison of self-perceived cardiovascular disease risk among smokers with Framingham and PROCAM scores: a cross-sectional analysis of baseline data from a randomised controlled trial. BMJ Open 2017;7:e012063.
Costa JA, Rodilla E, Cardona J, González C, Pascual JM. [Metabolic syndrome as a marker of cardiovascular events in hypertensives in primary prevention]. Med Clin (Barc) 2012;139:150–6 [Article in Spanish].
Carson AP, Howard G, Burke GL, Shea S, Levitan EB, Muntner P. Ethnic differences in hypertension incidence among middle-aged and older adults: the multi-ethnic study of atherosclerosis. Hypertension 2011;57:1101–7.
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting–enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145–53.
Rose G. The strategy of preventive medicine. New York: Oxford University Press; 1993.
Mancia G, Bombelli M, Facchetti R, Madotto F, Quarti-Trevano F, Polo Friz H, et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension 2009;54: 226–32.
Lieb W, Enserro DM, Sullivan LM, Vasan RS. Residual cardiovascular risk in individuals on blood pressure-lowering treatment. J Am Heart Assoc 2015;4:pii: e002155.
Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373:2103–16.
Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Hypertension 2018;71:e13–e115.
Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009;27: 1360–9.
Okin PM, Kjeldsen SE, Devereux RB. The relationship of all-cause mortality to average on-treatment systolic blood pressure is significantly related to baseline systolic blood pressure: implications for interpretation of the Systolic Blood Pressure Intervention Trial study. J Hypertens 2018;36:916–23.
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: ESC/ESH Task Force for the Management of Arterial Hypertension. J Hypertens 2018;36:2284–309.
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet 2017;389:37–55.
Gorostidi M, Sobrino J, Segura J, Sierra C, de la Sierra Á, Hernández del Rey R, et al. Ambulatory blood pressure monitoring in hypertensive patients with high cardiovascular risk: a cross-sectional analysis of a 20,000-patient database in Spain. J Hypertens 2007;25:977–84.
Shimbo D, Kent ST, Diaz KM, Huang L, Viera AJ, Kilgore M, et al. The use of ambulatory blood pressure monitoring among Medicare beneficiaries in 2007–2010. J Am Soc Hypertens 2014;8:891–7.
Pereira T, Paulino E, Maximiano S, Rosa M, Pinto AL, Mendes MJ, et al. Measurement of arterial stiffness and vascular aging in community pharmacies-The ASINPHAR@2action project. J Clin Hypertens (Greenwich) 2019;21:813–21.
Stergiou GS, Kyriakoulis KG, Kollias A. Pharmacy blood pressure: a common, useful, and neglected out of office blood pressure measurement method. J Hypertens 2017;35:1948–9.
Mensorio MS, Cebolla-Martí A, Rodilla E, Palomar G, Lisón JF, Botella C, et al. Analysis of the efficacy of an internet-based self-administered intervention (“Living Better”) to promote healthy habits in a population with obesity and hypertension: an exploratory randomized controlled trial. Int J Med Inform 2019;124:13–23.
Zanchetti A, Hennig M, Hollweck R, Bond G, Tang R, Cuspidi C, et al. Baseline values but not treatment-induced changes in carotid intima-media thickness predict incident cardiovascular events in treated hypertensive patients: findings in the European Lacidipine Study on Atherosclerosis (ELSA). Circulation 2009;120:1084–90.
Najjar SS, Scuteri A, Shetty V, Wright JG, Muller DC, Fleg JL, et al. Pulse wave velocity is an independent predictor of the longitudinal increase in systolic blood pressure and of incident hypertension in the Baltimore Longitudinal Study of Aging. J Am Coll Cardiol 2008;51:1377–83.
Kaess BM, Rong J, Larson MG, Hamburg NM, Vita JA, Levy D, et al. Aortic stiffness, blood pressure progression, and incident hypertension. JAMA 2012;308:875–81.
Koivistoinen T, Lyytikäinen LP, Aatola H, Luukkaala T, Juonala M, Viikari J, et al. Pulse wave velocity predicts the progression of blood pressure and development of hypertension in young adults. Hypertension 2018;71:451–6.
Benetos A, Adamopoulos C, Bureau JM, Temmar M, Labat C, Bean K, et al. Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. Circulation 2002;105:1202–7.
Wallace SML, Yasmin, McEniery CM, Mäki-Petäjä KM, Booth AD, Cockcroft JR, et al. Isolated systolic hypertension is characterized by increased aortic stiffness and endothelial dysfunction. Hypertension 2007;50:228–33.
McEniery CM, Wilkinson IB. The pressures of aging. Hypertension 2013;62:823–4.
AlGhatrif M, Lakatta EG. The conundrum of arterial stiffness, elevated blood pressure, and aging. Curr Hypertens Rep 2015;17:12.
Scuteri A, Morrell CH, Orrù M, Strait JB, Tarasov KV, Ferreli LAP, et al. Longitudinal perspective on the conundrum of central arterial stiffness, blood pressure, and aging. Hypertension 2014;64:1219–27.
Weber T, Wassertheurer S, Hametner B, Parragh S, Eber B. Noninvasive methods to assess pulse wave velocity: comparison with the invasive gold standard and relationship with organ damage. J Hypertens 2015;33:1023–31.
Hametner B, Wassertheurer S, Kropf J, Mayer C, Eber B, Weber T. Oscillometric estimation of aortic pulse wave velocity: comparison with intra-aortic catheter measurements. Blood Press Monit 2013;18:173–6.
Hametner B, Parragh S, Mayer C, Weber T, Van Bortel L, De Buyzere M, et al. Assessment of model based (input) impedance, pulse wave velocity, and wave reflection in the Asklepios cohort. PLoS One 2015;10:e0141656.
Feistritzer HJ, Klug G, Reinstadler SJ, Reindl M, Mayr A, Schocke M, et al. Oscillometric analysis compared with cardiac magnetic resonance for the assessment of aortic pulse wave velocity in patients with myocardial infarction. J Hypertens 2016;34:1746–51.
Feistritzer HJ, Reinstadler SJ, Klug G, Kremser C, Seidner B, Esterhammer R, et al. Comparison of an oscillometric method with cardiac magnetic resonance for the analysis of aortic pulse wave velocity. PLoS One 2015;10:e0116862.
Baumann M, Wassertheurer S, Suttmann Y, Burkhardt K, Heemann U. Aortic pulse wave velocity predicts mortality in chronic kidney disease stages 2–4. J Hypertens 2014;32: 899–903.
Ministerio de Sanidad, Servicios Sociales e Igualdad; 2016. Available from: https://www.mscbs.gob.es/estadEstudios/esta-disticas/sisInfSanSNS/tablasEstadisticas/InfAnualSNS2016/Informe_Anual_SNS_2016_completo.pdf.
Sehestedt T, Jeppesen J, Hansen TW, Wachtell K, Ibsen H, Torp-Petersen C, et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J 2010;31:883–91.
Sehestedt T, Jeppesen J, Hansen TW, Rasmussen S, Wachtell K, Ibsen H, et al. Thresholds for pulse wave velocity, urine albumin creatinine ratio and left ventricular mass index using SCORE, Framingham and ESH/ESC risk charts. J Hypertens 2012;30:1928–36.
Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. J Am Pediatr Med Assoc 2001;91:437–42.
Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 2010;63:e1–e37.
Eysenbach G. CONSORT-EHEALTH: improving and standardizing evaluation reports of web-based and mobile health interventions. J Med Internet Res 2011;13:e126.
Estadísticas de Colegiados y Farmacias Comunitarias. Consejo General de Colegios Oficiales de Farmacéuticos; 2017. Available from: https://www.elglobal.es/binrepository/video_content_394281_20180424161729.pdf.
Rodilla Sala E, Adell Alegre M, Giner Galvañ V, Perseguer Torregrosa Z, Pascual Izuel JM, Climent Catalá MT, et al. Arterial stiffness in normotensive and hypertensive subjects: frequency in community pharmacies. Med Clin (Barc) 2017;149:469–76 [Article in English, Spanish].
Nunan D, Fleming S, Hametner B, Wassertheurer S. Performance of pulse wave velocity measured using a brachial cuff in a community setting. Blood Press Monit 2014;19:315–19.
Luzardo L, Lujambio I, Sottolano M, da Rosa A, Thijs L, Noboa O, et al. 24-h ambulatory recording of aortic pulse wave velocity and central systolic augmentation: a feasibility study. Hypertens Res 2012;35:980–7.
Franssen PM, Imholz BP. Evaluation of the Mobil-O-Graph new generation ABPM device using the ESH criteria. Blood Press Monit 2010;15:229–31.
O’Brien E, Asmar R, Beilin L, Imai Y, Mancia G, Mengden T, et al. Practice guidelines of the European society of hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens 2005;23:697–701.
Sociedad Española de Farmacia Familiar y Comunitaria, SEFAC, Programa de Capacitación en Hipertensión Arterial, IMPACHTA. Available from: https://www.campussefac.org/impachta/inicio.
Crim MT, Yoon SS, Ortiz E, Wall HK, Schober S, Gillespie C, et al. National surveillance definitions for hypertension prevalence and control among adults. Circ Cardiovasc Qual Outcomes 2012;5:343–51.
The Reference Values for Arterial Stiffness’ Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’. Eur Heart J 2010;31:2338–50.
Author information
Authors and Affiliations
Corresponding author
Additional information
See Appendix 1: List of collaborating Community Pharmacists
Peer review under responsibility of the Association for Research into Arterial Structure and Physiology
Data availability statement: As a protocol, there are no data yet available.
Rights and permissions
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
About this article
Cite this article
Rodilla, E., Prats, R., Bellver, O. et al. Assessment of Arterial Stiffness by Brachial Oscillometry in Community Pharmacies for Managing Hypertension (COPHARTEN). Artery Res 25, 121–130 (2019). https://doi.org/10.2991/artres.k.191124.001
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2991/artres.k.191124.001